Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
For patients with obesity and elevated alk phos who have RA, do you check a fibroscan or serum NASH fibrosure test before starting methotrexate or leflunomide?
Related Questions
How would you manage a patient with erosive seronegative rheumatoid arthritis with IgG and IgM deficiency?
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
How do you approach treatment selection in patients with rheumatoid arthritis and severe COPD?
How do you approach treatment of early onset RA with minimal peripheral disease and aggressive cervical atlantoaxial involvement?
Would you re-challenge a patient with Rituximab who responded well in terms of their RA but developed symptomatic tachycardia after their first infusion?
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
What is your approach for cancer screening for elderly onset RA?
If subdeltoid bursitis, bicipital tenosynovitis, and femoroacetabular synovitis are commonly present in PMR, why are they not included in the criteria for PMR and how are they differentiated from elderly onset RA where presentation is often atypical and more proximal?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
